Literature DB >> 14618469

Body composition in advanced-stage Parkinson's disease.

M L Petroni1, G Albani, V Bicchiega, S Baudo, C Vinci, A Montesano, G Izzo, P Bertocco, S Mazzotta, E Zorzetto, F Balzola, A Mauro.   

Abstract

Little is known about body composition in Parkinson's disease (PD). We studied 35 patients (20 male, 15 female subjects; mean age 69.7+/-5.8 years) with advanced PD by anthropometry, dual-energy X-ray absorptiometry (DEXA), and serum 25-OH vitamin D measurement. Over 70% of patients had a disease duration of more than 4 years; all were on L-dopa treatment. Low levels of serum 25-OH vitamin D were present in 41% of the patients. The mean body mass index (BMI) was 25.3+/-4.3 kg/m(2) (range 17.1-37.3). Mid-arm muscle circumference was below the 10th percentile in 23%. For whole-body mean (+/-SD) bone mineral density, the T score was below -1 SD in 35% of patients, and the Z score was below -1 SD in 24%. Percent fat mass measured with DEXA was 30.6+/-11.4% (range 10.1-45.5) in the overall sample; it was 21.1+/-8.8% (range 10.1-30.4) in male subjects and 38.1+/-9.2% (range 25.8-45.5) in female subjects. We conclude that advanced-stage PD may show excess adiposity coexisting with depletion of lean body mass (sarcopenic obesity), in addition to decreased whole-body bone mineral density associated with low serum 25-OH vitamin D. A low level of physical activity and inadequate exposure to sunlight are likely to be among the putative causes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14618469     DOI: 10.1007/s00592-003-0062-6

Source DB:  PubMed          Journal:  Acta Diabetol        ISSN: 0940-5429            Impact factor:   4.280


  13 in total

1.  Body composition in Spinocerebellar ataxia type 3 and 10 patients: Comparative study with control group.

Authors:  Christiane de M B Almeida Leite; Maria Eliana M Schieferdecker; Caroline Frehner; Renato P Munhoz; Tetsuo Ashizawa; Hélio A G Teive
Journal:  Nutr Neurosci       Date:  2018-05-07       Impact factor: 4.994

2.  Prevalence and risk factors of osteoporosis in patients with Parkinson's disease.

Authors:  A Bezza; Z Ouzzif; H Naji; L Achemlal; A Mounach; M Nouijai; A Bourazza; R Mossadeq; A El Maghraoui
Journal:  Rheumatol Int       Date:  2008-07-01       Impact factor: 2.631

3.  Osteoporosis and Parkinson's disease.

Authors:  Laura Maria Raglione; Sandro Sorbi; Benedetta Nacmias
Journal:  Clin Cases Miner Bone Metab       Date:  2011-09

4.  The Impact of Dietary Intake and Physical Activity on Body Composition in Parkinson's Disease.

Authors:  Jessica Rivadeneyra; Okker Verhagen; Monica Bartulos; Natividad Mariscal-Pérez; Carla Collazo; Alvaro Garcia-Bustillo; Sara Calvo; Esther Cubo
Journal:  Mov Disord Clin Pract       Date:  2021-06-10

5.  Effects of moderate-volume, high-load lower-body resistance training on strength and function in persons with Parkinson's disease: a pilot study.

Authors:  Brian K Schilling; Ronald F Pfeiffer; Mark S Ledoux; Robyn E Karlage; Richard J Bloomer; Michael J Falvo
Journal:  Parkinsons Dis       Date:  2010-03-16

6.  Serum adiponectin levels in advanced-stage Parkinson's disease patients.

Authors:  Erica Cassani; Raffaella Cancello; Ferruccio Cavanna; Sabrina Maestrini; Anna Maria Di Blasio; Antonio Liuzzi; Gianni Pezzoli; Michela Barichella
Journal:  Parkinsons Dis       Date:  2011-06-16

7.  Mitochondrial therapy for Parkinson's disease: neuroprotective pharmaconutrition may be disease-modifying.

Authors:  Richard Kones
Journal:  Clin Pharmacol       Date:  2010-09-17

8.  Progressive resistance exercise and Parkinson's disease: a review of potential mechanisms.

Authors:  Fabian J David; Miriam R Rafferty; Julie A Robichaud; Janey Prodoehl; Wendy M Kohrt; David E Vaillancourt; Daniel M Corcos
Journal:  Parkinsons Dis       Date:  2011-11-24

9.  Assessment of nutritional status in patients with Parkinson's disease and its relationship with severity of the disease.

Authors:  Farzad Shidfar; Peivand Babaii Darabkhani; Leila Yazdanpanah; Siamak Karkheiran; Hamid Noorollahi-Moghaddam; Hamid Haghani
Journal:  Med J Islam Repub Iran       Date:  2016-12-19

10.  In vivo nuclear capture and molecular profiling identifies Gmeb1 as a transcriptional regulator essential for dopamine neuron function.

Authors:  Luis M Tuesta; Mohamed N Djekidel; Renchao Chen; Falong Lu; Wengang Wang; Bernardo L Sabatini; Yi Zhang
Journal:  Nat Commun       Date:  2019-06-07       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.